patients. Because the precise genetic change was unknown, the phenotype was assigned as a category 3 under the International Committee for Classification of Corneal Dystrophies classification, which accommodates disease variants in which no genetic locus has been identified (and therefore no known causative gene has been identified, either). 1, 4 Autosomal dominant bilateral corneal dystrophies involving the anterior corneal layers typically are associated with mutations in TGFBI 5 or PIP5K3. 6 We previously excluded mutations in these and other known corneal dystrophy genes in our family via a combination of microarray technology, direct Sanger sequencing, and linkage analysis. 3 A corneal dystrophy remarkably similar to the one observed in our New Zealand family recently was described as epithelial recurrent erosion dystrophy (ERED; Online Mendelian Inheritance in Man identifier, 122400). 1 Epithelial recurrent erosion dystrophy was described first by Franceschetti and Klein 7 and Franceschetti 8 in a large family. Genetic analysis of its members excluded the candidate corneal dystrophy genes TGFBI and TACSTD2. 9 Investigations into a similar phenotype in another family (originally described as Thiel-Behnke corneal dystrophy; Online Mendelian Inheritance in Man identifier, 602082) 10e12 linked the candidate genetic loci to chromosome 10q23e24, 12 although no causative mutation was identified.
Next-generation DNA sequencing technology has revolutionized the field of human genetics, allowing single basepair resolution of DNA variants at the protein-coding (exome) or whole-genome level. Recently, next-generation sequencing facilitated the association of ERED with a missense mutation in COL17A1 (Online Mendelian Inheritance in Man identifier, 113811). 13 In this article, we describe the identification of a heterozygous COL17A1 c.3156C/T mutation in the 06NZ-TRB1 ERED family via single nucleotide polymorphism microarray linkage analysis and next-generation exome sequencing. Segregation of the c.3156C/T COL17A1 mutation, which is predicted to be splice altering, was confirmed in additional 06NZ-TRB1 family members, as well as in 3 families located elsewhere in New Zealand, Tasmania, and the United Kingdom. We also identified a cosegregating, nonsynonymous variant in the DNAJC9 gene in our NZ06-TRB1 family that may modify disease presentation in these individuals. Finally, we confirmed functionally relevant expression of COL17A1 and DNAJC9 in both the human and zebrafish cornea.
Methods

Collection of DNA Samples
This study adhered to the principles of the Declaration of Helsinki and received institutional ethics approval (Northern A Health and Disability Ethics Committee, NTX/06/12/161; Northern Ireland Office for Research Ethics Committee, 350/03). After obtaining informed consent, genomic DNA was extracted from peripheral venous blood or saliva as described previously. 3 Samples were collected from 17 members of the 06NZ-TRB1 family (7 affected and 10 unaffected members) and from 4 members of the 15NZ-LED1 family (3 affected members and 1 member with unknown status). Samples from the additional families were received as genomic DNA from Tasmania (11 affected and 4 unaffected members) and the United Kingdom (7 affected and 2 unaffected members).
Clinical Examination of Patients
All family members underwent a comprehensive clinical examination to determine the presence or absence of disease (described previously 3 ). This included visual acuity, slit-lamp examination, intraocular pressure (Goldmann applanation tonometry), and, in selected affected individuals, clinical photography and in vivo confocal microscopy (IVCM) with the Heidelberg Retina Tomograph 2 Rostock Cornea Module (Heidelberg Engineering GMBH, Heidelberg, Germany). 3, 14 Representative IVCM images from all corneal layers were selected for the United Kingdom family (UKOGA) by 2 experienced examiners (B.S., V.R.) for analysis of pathologic changes. A validated IVCM grading scale for the quantification of anterior corneal stromal haze and fibrosis was applied. 15 
Linkage Analysis Using HumanLinkage-12 Arrays
HumanLinkage-12 arrays (Illumina, San Diego, CA) were used to genotype 17 06NZ-TRB1 family members (7 affected and 8 unaffected members and 2 members with unknown status subsequently confirmed as unaffected). Genotypes were imported into ALOHOMORA 16 for subsequent manipulation. Mendelian errors were identified with PedCheck, 17 and unlikely close-recombinant genotypes were identified with Merlin 18 and were removed before multipoint parametric linkage analysis with Allegro version 2 19 using the deCODE genetic map. 20 
Screening of Candidate Genes
Proteineprotein interactions were analyzed with Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). 21 This created functional protein association networks among known corneal dystrophy genes located within the reduced interval of the linkage region, identifying 8 genes of interest. Primer pairs for amplicons spanning at least 1 full exon, and its 5 0 and 3 0 introneexon boundaries, were designed with the National Center for Biotechnology Information's Primer-BLAST (available at www.ncbi.nlm.nih.gov/tools/primer-blast/) for all coding exons within the identified genes of interest, as shown in Supplemental  Table 1 (available at www.aaojournal.org). Sanger sequencing was performed on an ABI 3700 sequencer (Applied Biosystems, Waltham, MA) as previously described. 3, 22 Sequence chromatograms were compared with reference sequences in CodonCode Aligner version 4.2.3 (CodonCode Corporation, Centerville, MA).
Exome Sequencing and Bioinformatic Analysis
DNA from 2 affected individuals (II.5 and III.3, an uncleeniece pair; Fig 1A) was sent to the Otago Genomics Facility (New Zealand Genomics Ltd.) for library preparation, exome enrichment, and Illumina HiSeq sequencing (Illumina, Inc., San Diego, CA). Illumina TruSeq DNA sequencing libraries and TruSeq 64Mb exome enrichment were carried out according to the manufacturer's instructions. Exomes were subjected to 100bp paired-end sequencing using the Illumina HiSeq2000 instrument.
Reads were aligned to the human reference GRCh37 with Burrows-Wheeler Alignment tool (BWA). 23 Aligned reads then were marked for duplicates with Picard, 24 and base quality score recalibration and realignment of local insertions and deletions were performed with the Genome Analysis Toolkit. 25 Recalibrated reads were genotyped with the Genome Analysis Toolkit unified genotyper, 26 and variant quality scores were readjusted to standard hard filtering parameters.
Variants were annotated with SnpEff to identify genes, locations within genes, and possible impact on genes, 27 and then were filtered by the critical region (as defined by linkage), by heterozygosity in both affected family members, and finally by population allele frequency in ESP6500 28 and the 1000 Genomes data sets. 29 MutationTaster, 30 MutationTaster2, 31 and Human Splicing Factor 32 were used to predict the effect of variants on splicing. MutationTaster 30, 31 and PolyPhen-2 33 were used to predict pathogenicity of missense variants.
Sanger Sequencing Confirmation
Primer pairs flanking the variants of interest were designed with Pri-mer3Plus (available at: primer3plus.com/) and the National Center for Biotechnology Information's BLAST (Basic Local Alignment Search Tool; www.ncbi.nlm.nih.gov/BLAST). Primers for COL17A1 c.3156C/T were 5 0 -CGTGGGGAGAACATGTCC-3 0 (forward) and 5 0 -AAAGTCTCGCCTGTGATGGT-3 0 (reverse) and those for DNAJC9 c. 334 G/A were F: 5 0 -CCCTTCCCTGGTCCCTAGTT-3 0 (forward) and 5 0 -CTTGATGAACTGGTATGCCCA-3 0 (reverse).
Polymerase chain reaction (PCR) analysis was performed using the AmpliTaq Gold DNA polymerase (Life Technologies, Waltham, MA), with a final MgCl 2 concentration of 1.5 mmol/L. Polymerase chain reaction amplicons were purified using the DNA Clean & Concentrator-5 PCR Purification Kit (Zymo Research, Irvine, CA) according to the manufacturer's instructions. Sanger sequencing was performed on an ABI 3700 sequencer as described previously. 3, 22 Sequence data were compared with the National Center for Biotechnology Information reference sequence NM_000494.3 with Codon-Code Aligner Software version 4.2.3 (CodonCode Corporation).
Microsatellite Marker Analysis
Microsatellite markers were identified adjacent to COL17A1 with the UCSC Genome Browser microsatellite track. Microsatellite repeats were identified within COL17A1 (19ÂCA repeat; chr10:105815203e105815240, GRCh37) and OBFC1 (20ÂAT repeat; chr10:105674094e105674133), as shown in Supplemental Figure 1 (available at www.aaojournal.org). Primers were designed with Primer3Plus. Primers for COL17A1 (19ÂCA) were 5 0 -HEX-CCAAGACTGTGGTCCCACTT-3 0 (forward) and 5 0 -ACTCACTTCCAACTGCAGGA-3 0 (reverse; 60 C annealing temperature). Primers for OBFC1 (20ÂAT) were 5 0 -FAM-TGATTGTACCACTGCCTTCCA-3 0 (forward) and 5 0 -TCCACA ACCACAGCAAGACA-3 0 (reverse; 63 C annealing temperature). Polymerase chain reaction was performed on 250 ng DNA in a 50ml reaction with AmpliTaq Gold DNA Polymerase (Life Technologies) according to the manufacturer's guidelines. Polymerase chain reaction products were cleaned with the DNA Clean & Concentrator-5 PCR Purification Kit (Zymo Research) according to the manufacturer's instructions. The purified samples were run alongside a 500 LIZ Size Standard (Applied Biosystems) on an ABI 3730 capillary sequencer (Applied Biosystems). The microsatellite results were allele binned with the STRand analysis freeware (available at: www.vgl.ucdavis.edu/STRand).
Immunohistochemistry
Immunohistochemistry was performed to show expression of COL17A1 and DNAJC9 in both human and zebrafish cornea.
Cryosections of 16 to 20 mm were prepared from fresh keratoconic human corneal buttons (collected during corneal transplant surgeries; New Zealand Eye Bank, www.eyebank.org.nz/) and 4% paraformaldehydeetreated zebrafish tissue (isolated adult eyes and whole embryos) as follows. Tissues were processed though a sucrose gradient, embedded in a 2:1 25% sucroseeO.C.T. compound media (Tissue-Tek; Sakura Finetek U.S.A., Inc., Torrance, CA) and snap-frozen on dry ice, then stored at À80 C until use. Cryosections were mounted on Superfrost Plus Microscope Slides (Fisher Scientific, Hampton, NH) and dried overnight. For immunohistochemistry, sections were rehydrated in 0.1 M phosphatebuffered saline (PBS), then digested with 2 mg/ml testicular hyaluronidase for 1 hour at 37 C. Sections were permeabilized in À20 C methanol for 20 minutes, washed with 0.1 M PBS, and treated in 20 mmol/L glycine for 30 minutes. Sections then were blocked with 2% normal goat serum in PBS (plus 0.1% Triton X-100) for 30 minutes at room temperature before labelling. A mouse monoclonal antibody raised against the NC16a-domain of human COL17A1 (catalog no. ab79878; Abcam, Cambridge, UK) was used at a dilution of 1:40 for both species. For DNAJC9, a rabbit monoclonal antibody raised against a synthetic peptide corresponding to residues in human DNAJC9 (catalog no. EPR9856; Abcam) was used at a dilution of 1:100 for both species.
A polyclonal rabbit antimouse laminin (laminin, a 1) primary antibody (catalog no. L-9393; Sigma-Aldrich, St. Louis, MO) was used at 1:60 (8.3 ng/ml) to label the basement membrane. 34 The primary antibody was incubated overnight at 4 C in a humidifying chamber. Sections were washed with 0.1 M PBS before secondary antibody application. For COL17A1 detection, goat antimouse immunoglobulin G Alexa-546 (catalog no. A11003; Molecular Probes, Eugene, OR) at 1:1000 for human tissue and 1:400 for zebrafish tissue were used. Goat antirabbit immunoglobulin G Alexa-488 (catalog no. A11031; Life Technologies) was used at 1:300 (6.7 ng/ml) for laminin and DNAJC9 detection in both human and zebrafish tissue. Secondary antibody labelling was performed for 2 hours at room temperature in the dark to prevent quenching of the conjugated fluorophores. Unbound secondary antibody was removed by washing sections with 0.1 M PBS. Sections then were stained with 4 0 ,6-diamidino-2phenylindole to show cell nuclei and were mounted in Citiflour Antifadent-mounted media (Citifluor Ltd, London, UK). Labelling was visualized using confocal microscopy.
Zebrafish Whole-Mount In Situ Hybridization
Zebrafish were used with institutional ethics approval from the University of Auckland Animal Ethics Committee (reference no. 001343). Hybridization of antisense RNA probes specific to a transcript of interest were used to visualize expression via antibody-conjugated alkaline phosphatase staining. 35 Digoxigenin (Roche, Penzberg, Germany)elabelled antisense RNA probes were produced against zebrafish orthologs of COL17A1 (Col17a1a and Col17a1b, as previously published 36 ) and Dnacj9 (Ensembl transcript ENSDART00000137643, drDNAJC9_WISH_F2: AGAAGCTCCAGACTCGGAGA and drDNAJC9_WISH_R2: GCCCATCTCCTCCTGCATTT). Reverse-transcriptase PCR was performed on cDNA from embryos 8 days after fertilization to amplify the region of interest. The PCR products then were ligated into the pCR II-TOPO vector (Life Technologies), linearized with SpeI, NotI, or BamHI (NEB; New England Biolabs, Ipswich, MA), and transcribed with T7 or Sp6 polymerase. Embryos were prepared by fixation in 4% paraformaldehyde (ProSciTech, Thuringowa Central, Australia) overnight and stored in 100% methanol. An established whole-mount in situ hybridization protocol was followed as previously described. 35 Posthybridization staining was performed using an alkaline phosphataseeconjugated antidigoxigenin (DIG) antibody. Samples were imaged under a Leica MZ16FA stereomicroscope with a Leica DC490 camera and software (Leica, Wetzlar, Germany).
Morpholino Microinjections
Morpholinos were designed and synthesized by GeneTools LLC (Philomath, OR): Col17a1a_TB:TGGTTGTTGTTAGCTTGTC-CATTCC to target NM_001145565.1 and DNAJC9_SB_Disease:GTAATCTGCGGCAGAAGTGTCACAA to target exon 2 of ENSDART00000044150. The Standard Control Morpholino from GeneTools LLC was used as a control. Morpholinos were resuspended to 5-mmol/L stock solutions, from which 0.25-mmol/L (Col17a1a) and 0.5-mmol/L (Dnajc9 and control) injection mixes were made, including 2X Phenol Red dye. One nanoliter of morpholino was injected into single-cell embryos. Embryos were grown in the dark at 28 C and examined using a Zeiss Discover V20 stereo microscope and camera (Zeiss, Oberkochen, Germany).
Results
Phenotype Description
Four white families with suspected autosomal dominant ERED were identified independently ( Fig 1) . These families are not knowingly related to each other, nor to an ERED family previously described in New Zealand. 37 The phenotype of the index New Zealand family (06NZ-TRB1; Fig 1A) , as previously described, 3 was remarkably similar to the other 3 families (Table 1 ). In all families, affected individuals presented between 5 and 7 years of age for recurrent significant corneal epithelial erosions. As the individuals aged, these episodes tended to decrease in frequency and eventually burnt out, variably from the third to fourth decade. Symptoms continuing beyond the cessation of erosions predominantly were foreign body sensation, photophobia, and a variable reduction in vision.
All families had features on slit-lamp biomicroscopy similar to those described in the index family, additional examples of which are shown in Supplemental Figure 2 (available at www.aaojournal.org). 3 The key features of this 06NZ-TRB1 New Zealand corneal phenotype are a small number of focal, disc-shaped, circular, or wreath-like grey-white opacities (typically 0.2e1.5 mm in diameter) involving the Bowman layer and adjacent anterior stroma on a relatively subtle background of numerous smaller (<100 mm) grey flecks limited to the anterior 20% of the stroma (Fig 2) . The earliest lesions are similar in general appearance to the minor Bowman layer scarring that follows small, superficial corneal foreign bodies. Symptoms of recurrent corneal erosions typically commence at approximately Predicted 
6 years of age and seem to precede these corneal clinical signs.
Although there was a tendency for stromal opacities to appear and gradually increase throughout life, variable expression was present within family members. The phenotypic variability observed in the United Kingdom family in 4 individuals spanning 3 generations is demonstrated in Figure 2 .
In vivo confocal microscopy examination in the UKOGA family showed features similar to those in the index 06NZ-TRB1 New Zealand family: brightly hyperreflective polymorphous intraepithelial opacities were present in the epithelium, although invisible on biomicroscopic examination ( Fig 3A) . Areas with clinically visible disc-like opacities showed bowl-like epithelial thickening extending into the anterior stroma, with complete destruction of Bowman layer and the subepithelial nerve plexus ( Fig 3B) . The adjacent anterior stroma was remarkable for diffuse accumulation of anterior stromal extracellular matrix (grade 2; Fig  3C) . Although anterior stromal extracellular matrix accumulation was limited to focal clinical lesions in younger patients, it was not limited to these lesions in older individuals ( Fig 3D) . Also, the corneal stroma in younger patients did not yield any abnormal findings, whereas patients older than 60 years were found to show needle-like stromal opacities affecting the anterior more than the posterior stroma ( Fig 3E) , resembling findings previously described in granular and Reis-Bückler corneal dystropy. 15, 38 The corneal endothelium was not affected. Only single endothelial guttae were found in 1 female patient who was 74 years of age ( Fig 3F) .
Single Nucleotide Polymorphism Arrays Identify a Linkage Region
Genome-wide analysis of haplotypes conserved between 7 affected 06NZ-TRB1 family members identified a single peak on chromosome 10 reaching the maximum logarithm of the odds score of 2.7, as depicted in Supplemental Figure  3 (available at www.aaojournal.org). The linkage region corresponded to haplotypes between single nucleotide polymorphisms rs1111060 and rs11195400 (specifically, chr10:12,576,562e112,763,135, GRCh37) and covered 100.14 Mb, as shown in Supplemental Figure 4 (green haplotype; available at www.aaojournal.org). All 7 affected 06NZ-TRB1 individuals we examined carried this haplotype. Two individuals of unknown status (too young to have demonstrated disease) did not carry this haplotype and, by 10 years of age, did not demonstrate recurrent erosions. These individuals retrospectively had their status reassigned to unaffected, bringing the maximum logarithm of the odds score to 3.3.
Candidate Gene Screen in 06NZ-TRB1
The 100-Mb linkage region identified on chr10:12,576,562e112,763,135 contains approximately 996 genes. To identify candidate disease-causing genes, we created functional protein association networks between known corneal genes and those within our chr10:12,576,562e112,763,135 linkage region. 21 This identified 8 strong candidate genes of interest that are located within the reduced interval, expressed in the cornea, make biological sense, and interact with other known corneal proteins, as shown in Supplemental Table 2 (available at www.aaojournal.org). Sanger sequencing of all coding exons of these 8 candidate genes was performed on 2 brothers discordant for disease from the 06NZ-TRB1 family. No sequence variants were found in the genomic DNA sequences examined between these 2 individuals.
Exome Sequencing Results in 06NZ-TRB1
Given the size of the linkage region and the number of genes it contained, exome sequencing was performed on 2 affected individuals ( Fig 1A, II.5 and III.3, an uncleeniece pair). Bioinformatic filtering identified 46 heterozygous variants with allele frequencies of less than 0.001 in the National Heart, Lung, and Blood Institute ESP Exome Variant Server and 1000 Genomes databases, 28, 29 as shown in Supplemental Table 3 (available at www.aaojournal.org). 39 MutationTaster was used to predict pathogenicity of all heterozygous variants, as provided in Supplemental Table 3 (available at www.aaojournal.org). 30, 31 The evidence supporting 4 of the variants was poor because of low read depth; therefore, these variants were given a low priority and were not investigated further. Of the remaining 42 variants, 10 were homozygous in more than 4 individuals and a further 8 were heterozygous in more than 20 individuals in the 1000 Genomes Project data. 39 In total, we identified 8 potential disease-causing variants in our whole-genome exome sequencing data, as shown in Table 2 and Supplemental Table 4 (available at www.aaojournal.org).
Previously, Sullivan et al 40 identified an ERED phenotypeeassociated linkage region between markers D10S677 (chr10:95,964,310) and D10S1671 (chr10:106,852,499) in a family originally described as having Thiel-Behnke corneal dystrophy. 12 Four of our potential disease-causing variants lie in genes found within this region: ARHGAP19, COL17A1, GBF1, and SLIT1. COL17A1 previously was excluded as the causative gene in this previously described corneal dystrophy family. 40 However, the COL17A1 variant c.3156C/T, which superficially seems to produce a synonymous substitution in codon 1052 encoding glycine (chr10:105,797,446, GRCh37; ENST00000353479; NM_000494), segregated with disease in our original New Zealand family (06NZ-TRB1; 7 affected and 10 unaffected individuals), as confirmed by Sanger sequencing (Fig 1;   Table 1 ). This variant is present only once in the Exome Aggregation Consortium database (available at exac.broadinsititute.org/), with an allele frequency of 8.249e-06. 41 Jonsson et al 13 predicted (using a minigene splicing assay and in vitro mutagenesis) that the c.3156C/T variant leads to the introduction of a splice donor site and causes truncation of exon 46, resulting in the hypothesized insertion of 1 amino acid and deletion of 17 amino acids; (p.Gly1052_Thr1070delinsAla).
The only in silicoepredicted missense variant detected by whole-exome sequencing was in DNAJC9 (c.334G/A, p.D112N, chr10:75,005,922, GRCh37; NM_015190, exon 3), later confirmed by Sanger sequencing. This aspartic acid is conserved among all species (MutationTaster2), 31 and the change to asparagine is predicted to be probably damaging, with a PolyPhen-2 score of 0.999. We confirmed segregation of this variant with disease in all 17 of the 06NZ-TRB1 family members analyzed (7 affected and 10 unaffected individuals). This variant was allocated the dbSNP identifier rs200630658 and was reported at a heterozygote (C/T) frequency of 0.002 in exome sequencing data from 662 individuals (The ClinSeq Project 42 ). It is present twice in the Exome Aggregation Consortium database with an allele frequency of 1.65e-05. 41 
COL17A1 and DNAJC9 Variant Screening in Additional Pedigrees
Members from 3 subsequently identified ERED families underwent genetic screening at COL17A1 c.3156C/T and DNAJC9 c.334G/A, because segregation with disease status was confirmed in the 06NZ-TRB1 family at these 2 loci. A second affected family was identified in Tasmania, Australia (identifier, CDTAS1; Fig 1; Table 1 ). Clinically affected individuals in this pedigree showed recurrent ERED with a progressive increase in anterior stromal haze, similar to the 06NZ-TRB1 and UKOGA families (described above). The allelic status of 15 members of this family (10 affected and 5 unaffected individuals) for the COL17A1 variant c.3156C/T (p.Gly1052Gly, chr10:105,797,446, GRCh37; ENST00000353479; NM_000494) and DNAJC9 variant c.334G/A (p.D112N, chr10:75,005,922, GRCh37; NM_015190; Fig 1; Table 1 ) was determined with Sanger sequencing. All affected family members were heterozygous for the COL17A1 variant (C/T), whereas unaffected family members were homozygous (C/C). However, at the DNAJC9 variant c.334G/A, all individuals examined (10 affected and 5 unaffected) were homozygous for the wild-type c.334G allele. These results suggest that COL17A1 is causative of disease in this family.
A third affected family was identified in Hamilton, New Zealand (identifier, 15NZ-LED1; Fig 1; Table 1 ). This family demonstrated clinical features consistent with ERED. Of the 4 family members tested, 3 were affected and 1 was considered typically too young, at 6 years of age, to demonstrate symptoms. All 4 family members tested were heterozygous for the aberrant COL17A1 variant c.3156C/T. The DNAJC9 variant c.334G/A was not present in the 15NZ-LED1 family. Our results suggest that the youngest family member, although currently asymptomatic, likely will demonstrate signs of the disease in the near future.
The fourth family with ERED was identified in the United Kingdom (identifier, UKOGA; Fig 1; Table 1 ). Analysis of the variant loci confirmed segregation of COL17A1 c.3156C/T with disease (present in 7 affected members and absent in 2 unaffected members), but not DNAJC9 c.334G/A, which was not present in any family members. Table 5 , available at www.aaojournal.org). In the 06NZ-TRB1 family, 5 of 5 affected family members and 2 of 4 unaffected family members carry the C7/012 haplotype. All UKOGA family members tested carry the C7/012 haplotype (3 affected and 2 unaffected individuals), as with the 15NZ-LED1 family (3 affected individuals). In the CDTAS1 family, 9 of 9 affected family members carry the C7/012 haplotype, compared with only 1 of 4 unaffected family members.
Microsatellite Screening across Epithelial Recurrent Erosion Dystrophy Families
Expression of COL17A1 and DNAJC9 in Human Corneal Tissue
Immunohistochemistry analysis was used to examine expression of COL17A1 and DNAJC9 in a fresh keratoconic cornea (Fig 4) . COL17A1 is expressed in both corneal epithelial cells and the Bowman layer (basement membrane ; Fig 4, red) , whereas DNAJC9 is expressed in the Bowman layer of the corneal epithelium (Fig 4, green) . The pattern of DNAJC9 localization is distinct from that of COL17A1.
Expression of Col17a1 and Dnajc9 Proteins in Zebrafish
The Dnajc9 and Col17a1 staining in our adult (13 months after fertilization) zebrafish samples suggests protein presence in the external surface membranes of cells in the superficial squamous layer (Fig 5) . In embryonic fish 3 days after fertilization, Dnajc9 and Col17a1 are present throughout the 2-cell layer of the developing cornea (Fig 5) . Dnajc9 staining also appears to be present in the migrating endothelial cells, which at 3 days after fertilization are moving from the limbus to the cornea. 43 Both Col17a1 and Dnajc9 are expressed in different corneal layers in the adult zebrafish compared with human keratoconic tissue.
Expression of C0117a1 and Dnajc9 Transcripts in Zebrafish
At 50 hours after fertilization, the Col17a1a transcript is present in a punctate pattern on epithelial cells across the embryo, including the cornea (Fig 6) . The Col17a1b transcript is expressed within neuromast cells, consistent with previous observations by Kim et al, 36 and is absent in the cornea.
At 50 hours after fertilization, Dnajc9 is expressed throughout the head region of the embryo, including in the retinal proliferative zone, as described previously (Fig 6) . 44 There is no clear evidence to support corneal expression of Dnajc9 in embryos 50 hours after fertilization. However, under stress conditions induced by ethanol exposure, we observe upregulation of Dnacj9 in the head of embryos 2 days after fertilization, including the cornea, as shown in Supplemental Figure 5 (available at www.aaojournal.org).
Transient Knockdown of Col17a1a and Dnajc9 with Morpholinos
We transiently knocked down Col17a1a using a translationblocking morpholino. At 3 days after fertilization, we observed morphant embryos with atypical tail morphologic features, where the tip of the tail is distended compared with embryos injected with the standard morpholino control (Fig 7) . Several morphants demonstrated heart edema and spinal curvature (Fig 7, arrow) . No obvious changes were present in the morphant eye, although phenotypic characterization is limited by the sensitivity of this tissue to disruption during microdissection. When we transiently knocked down Dnajc9 with a spliceblocking morpholino, embryos 3 days after fertilization demonstrated a bent spine phenotype, which was not observed in control-injected morphants (Fig 7) . No obvious ocular phenotype was observed in the Dnajc9 morphants.
Discussion
In this study, we used genetic linkage to identify a haplotype on chr10:12,576,562e112,763,135 associated with autosomal dominant corneal ERED. Further characterization of the area with exome sequencing allowed us to show independently that the COL17A1 genomic variant c.3156C/T segregates with affected individuals and is likely to be causative of disease in the 06NZ-TRB1 family. The presence of this same variant in a further 3 white ERED families (15NZ-LED1, CDTAS1, and UKOGA) suggests that it is highly likely to be the causative mutation and is prevalent in autosomal dominant ERED. Jonsson et al 13 recently identified a missense mutation in COL17A1 (c.2816C/T, p.T939I) in a Northern Swedish family with ERED. A sequence variant in COL17A1 (c.3156C/T) identified in the misclassified Thiel-Benhke dystrophy 12 was reported as a nonpathogenic synonymous variant 40 ; however, Jonsson et al predicted that this variant leads to the introduction of a splice donor site and causes truncation of exon 46 (p.(Gly1052_Thr1070delinsAla)), and therefore is highly likely to be pathogenic. Combined with the findings in our 4 families described here, the c.3156C/T COL17A1 variant is causative and COL17A1 is an integral player in the pathogenesis of corneal ERED. In the index 06NZ-TRB1 New Zealand family, although numerous fine, small (25e100 mm), grey stromal flecks are present, it is the larger grey-white opacities at the level of the Bowman layer and immediately subjacent anterior stroma that distinguish the corneal phenotype from other corneal fleck dystrophies. Subtle corneal flecks are common yet asymptomatic and can be associated with contact lens wear, drugs, and inherited corneal dystrophies. Although on clinical biomicroscopy such flecks may appear to have a predominantly preeDescemet membrane stromal location (e.g., Maeder Danos) or anterior stromal location (e.g., Francois Neetans), more typically, and especially on assessment by in vivo confocal microscopy, these flecks are variably distributed throughout the stroma. 45, 46 Because these flecks typically are asymptomatic, there are few histologic data available, but they may represent enlarged or metabolically altered keratocytes or stromal deposits. 45e47 In the index 06NZ-TRB1 New Zealand family, the small grey flecks are limited to the very anterior 20% of stroma (clinically and by IVCM) and extend from the central to peripheral cornea. But these flecks are not in isolation unique to, or diagnostic of, the corneal phenotype. However, the larger, focal grey-white, predominantly disk-shaped, circular, or wreath-like lesions (with central clarity), which vary from 0.2 to 1.5 mm in diameter, in conjunction with these aforementioned small, grey anterior stromal flecks, seem to be clinically diagnostic of this variant fleck and anterior membrane dystrophy (see Supplemental Fig 2, available at www.aaojournal.org). The larger grey-white lesions typically are few (range, 5e10). Prominent corneal nerves are present variably, but this is not a feature unique to this dystrophy.
Based on the available genealogic information, the 4 ERED families we have described are not knowingly related to each other. Our haplotype analysis with flanking microsatellite markers suggests that a C7/012 haplotype cosegregates with the c.3156C/T COL17A1 variant in affected individuals. The discovery of this haplotype is consistent with a founder effect. Because the white population in Australia and New Zealand is derived largely from United Kingdom emigrants, it is possible that these families share a common ancestor.
There is biological evidence supporting an essential role of COL17A1 in the cornea. COL17A1, a member of the collagen family, is an integral part of the hemidesmosome structure. Our observed expression of COL17A1 in the corneal epithelium is consistent with its reported role as a hemidesmosome protein, 48, 49 suggesting a function biologically relevant to the ERED phenotype. Furthermore, COL17A1 is associated with other diseases characterized by compromised epithelial attachment. Autoimmunity against COL17A1 produces the skin-blistering disease bullous pemphigoid, 50 whereas mutations in COL17A1 cause the recessive, mechanically induced skin-blistering disease junctional epidermolysis bullosa, 51 which manifests as corneal erosion in many patients. 52 COL17A1 is linked to keratinocyte mobility, 53 and increased levels of COL17A1 have been observed during corneal wound healing, 54 suggesting it plays a crucial role not only in maintaining epithelial attachment, but also in recovering from injury. 53 Our expression analysis of human keratoconic corneal samples indicates that COL17A1 is present in the Bowman layer and around the epithelial cells, which is comparable with previous corneal findings. 13, 55, 56 Although our expression analysis was performed on keratoconic cornea, no difference in COL17A1 expression is found between keratoconic and normal corneal tissue. 13, 56 We identified a second potentially pathogenic variant in our original New Zealand family (06NZ-TRB1) in the DNAJC9 gene (c.334G/A, p.D112N); this is the only variant identified in our exome sequencing data set (after filtering) that is a clear missense change. DNAJC9 is a member of the heat shock (HSP40) family of proteins and is purported to have a role in the molecular chaperoning of HSP70 family members. In human tissue, DNAJC9 is expressed ubiquitously and is upregulated in response to stress. 57 Because the nonsynonymous DNAJC9 variant is found in only 1 of the 4 ERED families (06NZ-TRB1), we conclude that it is not necessary for ERED corneal disease, but it cannot be excluded as a modifier of disease severity. Of note, disease presentation in the 06NZ-TRB1 family trended toward an earlier age at onset than in the (Table 1) . DNAJC9 expression has not been characterized previously in the human cornea. The expression pattern within the human keratoconic cornea is consistent with a potential role in corneal adhesion. Colocalization of DNAJC9 and COL17A1 in both human and zebrafish cornea is suggestive of a potential interaction between the 2 proteins, possibly with regard to response to injury and tissue regeneration. We hypothesize that under stress conditions, such as mild trauma, mutant DNAJC9 protein may not adequately perform its roles in regulating cell proliferation, survival, and apoptosis by chaperoning HSP70s.
In addition, we examined the expression pattern of COL17A1 and DNAJC9 orthologs (protein and transcript) in the zebrafish. The zebrafish cornea contains all 5 of the major corneal layers (including the Bowman layer) and is readily visible early in development. 43 The mature zebrafish corneal epithelium is 4 to 6 cells deep, constituting approximately 60% of the corneal thickness, whereas the stroma comprises a further 30%. 43 Although we did observe Col17a1 and Dnajc9 in the zebrafish cornea, these proteins appeared to be localized to the squamous epithelial cells on the surface of the cornea. The difference in protein localization between the zebrafish and human corneas may be attributed to the differences in cornea between these 2 species; the zebrafish cornea presumably is under less mechanical stress than the human cornea (absence of eyelids in the fish). Therefore, zebrafish epithelial cells may not require the same tight anchoring to the Bowman layer. The zebrafish has undergone historical genome duplication, 58 resulting in 2 copies of many genes, some of which have undergone functional divergence. Whole-mount in situ hybridization analysis of gene expression was used to identify the zebrafish corneal ortholog of human COL17A1 in zebrafish embryos. The expression of the COL17A1 homologs has been assessed previously in zebrafish with regard to junctional epidermolysis bullosa mutations. 36 We confirmed the previously published expression patterns of the zebrafish orthologs of COL17A1:Col17a1a and Col17a1b, 36, 44 and established that Col17a1a is likely to be the functional ortholog in zebrafish cornea. We did not observe high expression of Dnajc9 in embryos; however, as a member of the heat shock protein family, high expression is not necessarily expected from embryos in the absence of stress. Under stress conditions induced by ethanol exposure, 59 we noted increased Dnajc9 expression in the zebrafish cornea. When Col17a1a was knocked down transiently during early development, we observed changes to tail morphologic features, but no obvious alteration to the gross corneal or ocular phenotype. A similar tail distension phenotype was characterized by Kim et al, 36 who identified the phenotype as resulting from vacuolization in the epidermis and attributed it to compromised hemidesmosomes. Transient knockdown of Dnajc9 caused spinal curvature in some morphants. Accurate characterization of the cornea of the developing zebrafish is challenging because morphologic artefacts are introduced readily during the microdissection process. As a further limitation, the zebrafish cornea is not developed fully until adulthood, 43 challenging the feasibility of transient, morpholino-induced gene knockdowns.
Until recently, morpholinos were considered the gold standard approach; however, phenotypic discrepancies now are known to be common between morphant and knockout zebrafish. 60 The CRISPR/Cas9 genome-editing technique opens up exciting opportunities to introduce (via homologydirected repair) our identified COL17A1 and DNAJC9 variants into zebrafish, 61 establishing lines suitable for examining the role of these genes in adult zebrafish cornea using both ophthalmic (e.g., optical coherence tomography 62 ) and molecular diagnostic tools. We have found that although the zebrafish is an ideal model for genetic engineering of the Col17a1a variant c.3156C/T, it has limitations for use in examining corneal dystrophy onset during early development.
The rare COL17A1 disease-causing variant (c.3156C/T) occurring in our 4 families with phenotypically similar disease replicates the association of a COL17A1 missense mutation (c.2816C/T) in the Swedish ERED family. 13 It also suggests that the phenotype described as Thiel-Behnke by Yee et al 12 is the result of the same COL17A1 disease-causing variant detected in our families. This study expands the phenotypic spectrum of COL17A1 disease from autosomal recessive epidermolysis bullosa to autosomal dominant ERED and suggests that COL17A1 is a key protein in maintaining corneal epithelium integrity.
